Novartis AG 2025 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Novartis AG
Reporting Period: Fiscal year ended December 31, 2025
Filing Date: February 4, 2026
Business Overview: Novartis is a global innovative medicines company focused on four core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; and oncology. Following the 2023 spin-off of its Sandoz generics business, the company operates as a single global segment dedicated to innovative medicines. The company employs approximately 75,267 full-time equivalents globally.
Key Financial Metrics (2025 vs. 2024)
| Metric (USD Millions) | 2025 | 2024 | Change (%) |
|---|---|---|---|
| Net Sales (Continuing Ops) | 54,532 | 50,317 | +8% |
| Operating Income | 17,644 | 14,544 | +21% |
| Operating Margin | 32.4% | 28.9% | +3.5 pts |
| Net Income | 13,967 | 11,939 | +17% |
| Basic EPS | $7.21 | $5.92 | +22% |
| Free Cash Flow | 17,596 | 16,253 | +8% |
| Net Debt | 21,947 | 16,141 | +36% |
| Total Debt | 33,537 | 29,598 | +13% |
Note: Growth rates are reported in USD. Constant currency growth was 8% for net sales and 25% for operating income.
Material Changes and Drivers
- Sales Growth: Driven primarily by volume growth (+15 percentage points). Key growth drivers included Kisqali (+58%), Scemblix (+87%), Pluvicto (+43%), Kesimpta (+37%), and Cosentyx (+9%).
- Headwinds: Sales were negatively impacted by generic competition (-6 percentage points), particularly affecting Entresto (US generic entry in Q3 2025), Promacta/Revolade, and Tasigna.
- Profitability: Operating income margin expanded to 32.4% due to higher net sales and lower impairment charges compared to the prior year, partially offset by increased investments in priority brands.
- Acquisitions: In 2025, Novartis completed acquisitions of Anthos Therapeutics, Regulus Therapeutics, and Tourmaline Bio (accounted for as asset acquisitions). A proposed acquisition of Avidity Biosciences (approx. $12 billion) was announced in October 2025.
- Impairments: The company recorded impairment charges of $557 million on intangible assets in 2025, a significant decrease from $1.4 billion in 2024 (which included a $900 million goodwill impairment related to MorphoSys).
Guidance, Outlook, and Risks
- Outlook: Management maintains a focus on delivering high-value medicines and operational excellence. The company achieved its 2027 core margin target (40.1%) two years ahead of schedule.
- Regulatory & Pricing Risks:
- US Pricing: The company faces ongoing pressure from the Inflation Reduction Act (IRA). Entresto is subject to price negotiation for 2026. Cosentyx, Kisqali, and Xolair were selected for the 2028 negotiation round. In December 2025, Novartis entered a voluntary agreement with the US administration regarding drug pricing and access.
- Patent Expirations: Entresto lost US market exclusivity in July 2025. Mekinist faces patent challenges in the US (2027) and EU (2029).
- Strategic Risks: Key risks include the success of new product launches, the ability to replace revenue lost to generics, cybersecurity threats, and geopolitical tensions affecting supply chains and trade tariffs.
- Capital Allocation: The company continues a robust share buyback program. In 2025, it repurchased approximately 77.6 million shares for $8.9 billion. A new up-to $10 billion buyback authorization was approved in July 2025.
Key Facts for Investor Verification
- Entresto Exposure: Verify the magnitude of sales decline in the US following generic entry in Q3 2025 and the status of ongoing litigation to protect IP rights.
- IRA Impact: Monitor the implementation of the Medicare Drug Price Negotiation Program for Entresto (2026) and the selection of Cosentyx, Kisqali, and Xolair for 2028.
- Avidity Biosciences Acquisition: Track the closing conditions and regulatory approval status for the proposed $12 billion acquisition of Avidity Biosciences, expected to close in H1 2026.
- Debt Levels: Note the increase in net debt to $21.9 billion, driven by bond issuances ($6.0 billion in 2025) and acquisitions, though the company maintains strong credit ratings (Aa3/P-1 from Moody's; AA-/A-1+ from S&P).
- Core Margin Achievement: Confirm the sustainability of the 40.1% core operating margin, which was achieved two years ahead of the company's 2027 target.